National MS Society: "BTK Inhibitor" Tolebrutinib Does Not Meet Primary Endpoint in Phase 3 Trial in People With Primary Progressive MS
December 16, 2025
December 16, 2025
NEW YORK, Dec. 16 -- The National Multiple Sclerosis Society issued the following news:
* * *
"BTK Inhibitor" Tolebrutinib Does Not Meet Primary Endpoint in Phase 3 Trial in People with Primary Progressive MS
Further Delay Expected in FDA Review for Non-Relapsing Secondary Progressive MS
Sanofi, Inc. announced that tolebrutinib (an experimental, oral BTK-inhibitor) did not meet the primary endpoint of delaying time to disability progr . . .
* * *
"BTK Inhibitor" Tolebrutinib Does Not Meet Primary Endpoint in Phase 3 Trial in People with Primary Progressive MS
Further Delay Expected in FDA Review for Non-Relapsing Secondary Progressive MS
Sanofi, Inc. announced that tolebrutinib (an experimental, oral BTK-inhibitor) did not meet the primary endpoint of delaying time to disability progr . . .